Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Longitude Capital

Investor type Venture Capital
Founders David Hirsch Marc Galletti Patrick Enright


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 112
Average round size
The average size of a deal this fund participated in
Portfolio companies 76
Rounds per year 6.59
Lead investments 30
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 28
Key employees 7
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Health Care
  • Biotechnology
  • Medical
  • Pharmaceutical
  • Therapeutics

Longitude Capital appeared to be the VC, which was created in 2006. The fund was located in North America if to be more exact in United States. The leading representative office of defined VC is situated in the Menlo Park.

Among the most successful fund investment fields, there are Health Diagnostics, Therapeutics. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Alphaeon, CardioDx, SutroVax. The fund has exact preference in a number of founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little. For fund there is a match between the location of its establishment and the land of its numerous investments - United States.

The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the Longitude Capital, startups are often financed by Kleiner Perkins, The Carlyle Group, TVM Capital. The meaningful sponsors for the fund in investment in the same round are RA Capital Management, OrbiMed, Kleiner Perkins. In the next rounds fund is usually obtained by RA Capital Management, Rock Springs Capital, Kleiner Perkins.

The current fund was established by Marc Galletti, Patrick Enright. We also calculated 7 valuable employees in our database.

The common things for fund are deals in the range of 10 - 50 millions dollars. Opposing the other organizations, this Longitude Capital works on 1 percentage points less the average amount of lead investments. The real fund results show that this VC is 23 percentage points more often commits exit comparing to other companies. The increased amount of exits for fund were in 2018. When the investment is from Longitude Capital the average startup value is 500 millions - 1 billion dollars. The high activity for fund was in 2015. Despite it in 2019 the fund had an activity. The fund is constantly included in 2-6 deals per year.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Longitude Capital:
Typical Co-investors
Longitude Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Longitude Capital:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
a16z Cultural Leadership Fund -
BorgWarner Auburn Hills, Michigan, United States
Costanoa Ventures California, Palo Alto, United States
Davidson Capital Group Florida, Santa Rosa Beach, United States
Dongguan Xiangwei Chuangye Touzi Hehuo Qiye China, Dongguang, Guangdong
Excubator Bangalore, India, Karnataka
Global Alliance for Genomics & Health Canada, Ontario, Toronto
GoldPoint Partners New York, New York, United States
Katalysator AS Norway, Oslo
Mauritius Investments Mauritius, Port Louis, Port Louis
Midea Group China, Guangdong Province, Huizhou
Prime Value Capital Management Beijing, Beijing, China
Santai Holding Chengdu, China, Sichuan
Shenzhen Jiacaili Zican China, Guangdong, Shenzhen
Stena Sessan Stockholm, Stockholm County, Sweden
Toyo Tsushin Kogyo Japan, Yamanashi, Yamanashi Prefecture
Westwood Ventures New York, New York, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation


Health Care
$34M31 Jan 2023 Chicago, Illinois, United States

Alpha9 Theranostics

Product Research
$75M14 Dec 2022 Vancouver, British Columbia, Canada

Opna Bio

Health Care
$38M21 Nov 2022 Epalinges, Vaud, Switzerland

CG Oncology

Health Care
Health Diagnostics
$120M15 Nov 2022 Irvine, California, United States

Zenas BioPharma

Health Care
$118M07 Nov 2022 -

Rivus Pharmaceuticals

Health Care
$132M22 Sep 2022 Charlottesville, Virginia, United States


Health Care
Staffing Agency
$115M06 Apr 2022 Quincy, Massachusetts, United States

LimFlow SA

Emergency Medicine
Health Care
Medical Device
$42M05 Apr 2022 Paris, Ile-de-France, France


Health Care
Health Diagnostics
$325M22 Feb 2022 Virginia, United States
Sydnexis Secures $45 Million Series B Financing Led by Visionary Ventures and Blue Stem Capital

– Sydnexis, Inc. completed a $45m Series B financing led by Visionary Ventures, Blue Stem Capital, and SC Master Fund, with participation from existing investors RA Capital Management, Longitude Capital, and Medicxi.
– The financing will be used to fund Sydnexis’ lead candidate, SYD-101, through completion of the fully enrolled pivotal Phase 3 STAAR study for the treatment of progressive myopia in children.
– Sydnexis’ STAAR study is the largest pediatric myopia study globally to investigate the use of low dose atropine to retard progressive myopia. In this study, Sydnexis is evaluating two different concentrations of its proprietary atropine formulation SYD-101 (0.01% and 0.03%) versus a placebo control group.

Cortica Raises $60M in Series C Funding

– Cortica from San Diego CA is focused on clinical services for autism and other neurodevelopmental conditions.
– Series C $60m funding round was led by Longitude Capital with participation from 406 Ventures, Adam Boehler, Questa Capital and Aperture Venture Partners and Silicon Valley Bank.
– The new financing will be used to accelerate growth, expand centers across multiple states, and investigate novel drug, device, and diagnostic technologies through sponsored and NIH-funded research.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Longitude Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: